Pharmaceuticals

The pharmaceutical industry has been for decades one of the most profitable worldwide. Serious challenges, such as the expiry of long-term lucrative patents (Lipitor, to mention just one) and the cuts in healthcare and R&D in many countries worldwide, can pose a challenge to the growth of the industry. Which drug can save the life of the pharmaceutical industry? Highly differentiated strategies: this is what companies should focus on now if they want to stay competitive. Do you want to know more?

You can get a detailed picture of the market and refine your marketing, brand, and sales strategies with the reliable, up-to-date business information provided by the extensive range of reports, books and subscriptions listed under Research and Markets’ Pharmaceuticals category. They cover markets, companies (big Pharma, mid-sized specialty pharmaceutical companies, generic manufacturers, and small firms), technologies, e-healthcare, pharmaeconomics, drug discovery, and drug delivery.

The product coverage is huge. It includes OTC drugs as well disorder and goal-specific products related to respiration, oncology, vitamins, cardio, analgesics, central nervous system, generics, immune disorders, and women’s health. Show Less ... more

• Chronic Lymphocytic Leukemia

  EURO€ 154.00USD$ 200.00GBP£ 129.00AUD$ 196.00JPY¥ 19,747.00SEK 1 313,00CHF 189.00CAD$ 204.00 Informa Healthcare, Oct 2008 , Pages: 312
  Written by authors from the world’s most prominent cancer centers, Chronic Lymphocytic Leukemia supplies a comprehensive, up-to-date picture of CLL and how to better treat patients inflicted with the...

• European Cancer IVD Market

  EURO€ 4,996.00USD$ 6,500.00GBP£ 4,203.00AUD$ 6,357.00JPY¥ 641,764.00SEK 42 678,00CHF 6'126.00CAD$ 6,623.00 Frost & Sullivan, Oct 2008 , Pages: 114
  This strategic analysis service provides a detailed analysis of the European Cancer IVD market An in-depth analysis of marketing parameters (revenues, forecasts, geographic trends and market share)...

• Switzerland Pharmaceuticals and Healthcare Report Q4 2008

  EURO€ 874.00USD$ 1,137.00GBP£ 735.00AUD$ 1,112.00JPY¥ 112,215.00SEK 7 462,00CHF 1'071.00CAD$ 1,158.00 Business Monitor International, Oct 2008 , Pages: 70
  The Switzerland Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Switzerland's pharmaceuticals and healthcare industry Despite the modest size of...

• Netherlands Pharmaceuticals and Healthcare Report Q4 2008

  EURO€ 874.00USD$ 1,137.00GBP£ 735.00AUD$ 1,112.00JPY¥ 112,215.00SEK 7 462,00CHF 1'071.00CAD$ 1,158.00 Business Monitor International, Oct 2008 , Pages: 75
  This Netherlands Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Netherlands' pharmaceuticals and healthcare industry Growth in the drug market should...

• Czech Republic Pharmaceuticals and Healthcare Report Q4 2008

  EURO€ 874.00USD$ 1,137.00GBP£ 735.00AUD$ 1,112.00JPY¥ 112,215.00SEK 7 462,00CHF 1'071.00CAD$ 1,158.00 Business Monitor International, Oct 2008 , Pages: 70
  The Czech Republic Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Czech Republic's pharmaceuticals and healthcare industry The US$3 64bn Czech drug...

• Poland Pharmaceuticals and Healthcare Report Q4 2008

  EURO€ 874.00USD$ 1,137.00GBP£ 735.00AUD$ 1,112.00JPY¥ 112,215.00SEK 7 462,00CHF 1'071.00CAD$ 1,158.00 Business Monitor International, Oct 2008 , Pages: 69
  The Poland Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Poland's pharmaceuticals and healthcare industry The Polish drug market is set for modest...

• Slovenia Pharmaceuticals and Healthcare Report Q4 2008

  EURO€ 874.00USD$ 1,137.00GBP£ 735.00AUD$ 1,112.00JPY¥ 112,215.00SEK 7 462,00CHF 1'071.00CAD$ 1,158.00 Business Monitor International, Oct 2008 , Pages: 65
  This Slovenia Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Slovenia's pharmaceuticals and healthcare industry In the Business Environment Ranking...

• Lithuania Pharmaceuticals and Healthcare Report Q4 2008

  EURO€ 874.00USD$ 1,137.00GBP£ 735.00AUD$ 1,112.00JPY¥ 112,215.00SEK 7 462,00CHF 1'071.00CAD$ 1,158.00 Business Monitor International, Oct 2008 , Pages: 65
  This Lithuania Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Lithuania's pharmaceuticals and healthcare industry In the Business Environment Ranking...

• Nursing Medical Emergency Patients. Essential Clinical Skills for Nurses

  EURO€ 35.00USD$ 46.00GBP£ 30.00AUD$ 45.00JPY¥ 4,504.00SEK 300,00CHF 43.00CAD$ 46.00 John Wiley and Sons Ltd, Oct 2008 , Pages: 336
  Nursing Medical Emergency Patients is a practical guide to the nursing care and management of patients with medical emergencies involving system failure. Following an initial chapter on assessment,...

• Amgen's denosumab - New hope for old bones revisited

  EURO€ 1,153.00USD$ 1,500.00GBP£ 970.00AUD$ 1,467.00JPY¥ 148,099.00SEK 9 849,00CHF 1'414.00CAD$ 1,528.00 LifeTech Research, Oct 2008 , Pages: 52
  A review of denosumab's safety profile throughout its entire clinical program (osteoporosis, cancer and rheumatoid arthritis), and a discussion of potential regulatory issues and implications In addition,...

• Adrenal Toxicology. Target Organ Toxicology Series

  EURO€ 192.00USD$ 250.00GBP£ 162.00AUD$ 245.00JPY¥ 24,683.00SEK 1 641,00CHF 236.00CAD$ 255.00 Informa Healthcare, Oct 2008 , Pages: 352
  Despite being regarded as the most common toxicological target in the endocrine system, the adrenal gland has often been neglected in regulatory testing. Adrenal Toxicology addresses the increased interest...

• Strategic Perspectives: Antidyslipidemics - Current Market is not Conducive for Growth

  EURO€ 11,684.00USD$ 15,200.00GBP£ 9,830.00AUD$ 14,867.00JPY¥ 1,500,741.00SEK 99 801,00CHF 14'327.00CAD$ 15,488.00 Datamonitor, Oct 2008 , Pages: 223
  The antidyslipidemic market is increasingly governed by cost concerns which appear to be more pressing than the safety and efficacy concerns. Cost-saving initiatives together with the continuing genericization...

• M&A Trends in Pharma

  EURO€ 8,763.00USD$ 11,400.00GBP£ 7,372.00AUD$ 11,150.00JPY¥ 1,125,556.00SEK 74 851,00CHF 10'745.00CAD$ 11,616.00 Datamonitor, Oct 2008 , Pages: 144
  M&As have been the preferred growth strategy by a majority of Pharma companies. Although mega-mergers certainly create economies of scale and boost pipelines, the long-term effects may not be as favorable...

• Pharmaceutical Market and Health Care Reform in China 2008

  EURO€ 1,522.00USD$ 1,980.00GBP£ 1,280.00AUD$ 1,937.00JPY¥ 195,491.00SEK 13 000,00CHF 1'866.00CAD$ 2,018.00 Seed Planning, Oct 2008 , Pages: 145
  With total pharmaceutical production reaching RMB 648 9bn in 2007, the Chinese pharmaceutical market has continued to maintain a two-digit growth dynamics On the other hand, there remain a number of...

• Safety Evaluation in the Development of Medical Devices and Combination Products. Edition No. 3

  EURO€ 192.00USD$ 250.00GBP£ 162.00AUD$ 245.00JPY¥ 24,683.00SEK 1 641,00CHF 236.00CAD$ 255.00 Informa Healthcare, Oct 2008 , Pages: 504
  Capturing the growth of the global medical device market in recent years, this practical new guide is essential for all who are responsible for ensuring safety in the use and manufacture of medical...

• Issues; Trends and Prevalence in the European Cancer Therapy Market- Non Pharmaceutical

  EURO€ 4,996.00USD$ 6,500.00GBP£ 4,203.00AUD$ 6,357.00JPY¥ 641,764.00SEK 42 678,00CHF 6'126.00CAD$ 6,623.00 Frost & Sullivan, Oct 2008 , Pages: 160
  This research service examines the Issues, trends and prevalence in the European cancer therapy market in terms of the challenges faced by market participants, drivers, and restraints in the industry,...

• Latvia Pharmaceuticals and Healthcare Report Q4 2008

  EURO€ 874.00USD$ 1,137.00GBP£ 735.00AUD$ 1,112.00JPY¥ 112,215.00SEK 7 462,00CHF 1'071.00CAD$ 1,158.00 Business Monitor International, Oct 2008 , Pages: 60
  This Latvia Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Latvia's pharmaceuticals and healthcare industry In the Business Environment Ranking...

• European Insulin Delivery Devices Market

  EURO€ 4,996.00USD$ 6,500.00GBP£ 4,203.00AUD$ 6,357.00JPY¥ 641,764.00SEK 42 678,00CHF 6'126.00CAD$ 6,623.00 Frost & Sullivan, Oct 2008 , Pages: 90
  This research service examines the European insulin delivery devices markets in terms of the challenges faced by market participants, drivers and restraints in the industry, the competitive structure...

• Cost Containment and Efficiency in National Health Systems. Health Care and Disease Management

  EURO€ 107.00USD$ 139.00GBP£ 90.00AUD$ 136.00JPY¥ 13,741.00SEK 914,00CHF 131.00CAD$ 142.00 John Wiley and Sons Ltd, Oct 2008 , Pages: 247
  Written by a local health economics expert, each of the eight chapters in this timely handbook and ready reference describes the national healthcare system of a different industrialized country. In...

• Clinical Laboratory Investigation and Psychiatry. A Practical Handbook

  EURO€ 154.00USD$ 200.00GBP£ 129.00AUD$ 196.00JPY¥ 19,747.00SEK 1 313,00CHF 189.00CAD$ 204.00 Informa Healthcare, Oct 2008 , Pages: 544
  A precise, practical handbook, Clinical Laboratory Investigation and Psychiatry is an invaluable tool that explores day-to-day psychiatric practices and various situations that arise in the field of...

• Currently Druggable in Melanoma: A Drug Target Competitive Analysis

  EURO€ 1,950.00USD$ 2,537.00GBP£ 1,641.00AUD$ 2,481.00JPY¥ 250,475.00SEK 16 657,00CHF 2'391.00CAD$ 2,585.00 Bioseeker, Oct 2008 , Pages: 268
  This report aims to analyze the current and future potential of melanoma pipeline by examining key fundamentals across the entire pipeline of drug candidates The author has identified three fundamental...

• Molecular Imaging in Oncology

  EURO€ 307.00USD$ 400.00GBP£ 259.00AUD$ 391.00JPY¥ 39,493.00SEK 2 626,00CHF 377.00CAD$ 408.00 Informa Healthcare, Oct 2008 , Pages: 744
  With molecular imaging becoming one the fastest growing topics in medical schools, Informa Healthcare presents Molecular Imaging in Oncology, the first comprehensive reference on molecular imaging in...

• China HealthCare & Pricing System Reform 2008

  EURO€ 922.00USD$ 1,200.00GBP£ 776.00AUD$ 1,174.00JPY¥ 118,480.00SEK 7 879,00CHF 1'131.00CAD$ 1,223.00 Liang Kong, Oct 2008 , Pages: 162
  China represents one of the fastest growing pharmaceutical markets in the world and is the most lucrative market in Asia Since 1978, the annual growth rate for China’s pharmaceutical market volume has...

• Cost Estimating Manual for Water Treatment Facilities

  EURO€ 107.00USD$ 139.00GBP£ 90.00AUD$ 136.00JPY¥ 13,741.00SEK 914,00CHF 131.00CAD$ 142.00 John Wiley and Sons Ltd, Oct 2008 , Pages: 224
  Tested-and-proven techniques for quick, accurate estimates Here is the first manual that guides engineers, planners, and contractors through the process of estimating the cost of building water treatment...

• Mexico Pharmaceuticals and Healthcare Report Q4 2008

  EURO€ 874.00USD$ 1,137.00GBP£ 735.00AUD$ 1,112.00JPY¥ 112,215.00SEK 7 462,00CHF 1'071.00CAD$ 1,158.00 Business Monitor International, Oct 2008 , Pages: 76
  Mexico Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Mexico's pharmaceuticals and healthcare industry Mexico’s drug market was valued at MXN132...

• The Form FDA 1572: A Reference Guide for Clinical Researchers, Sponsors, and Monitors

  EURO€ 48.00USD$ 45.00GBP£ 27.00AUD$ 66.00JPY¥ 5,522.00SEK 388,00CHF 65.00CAD$ 60.00 Cambridge Healthtech Institute, Oct 2008 , Pages: 134
  This year alone, well over 20,000 clinical investigators from around the globe will complete the mandatory Form FDA 1572-Statement of Investigator before participating in FDA-regulated clinical trials...

• Australia Pharmaceuticals and Healthcare Report Q4 2008

  EURO€ 874.00USD$ 1,137.00GBP£ 735.00AUD$ 1,112.00JPY¥ 112,215.00SEK 7 462,00CHF 1'071.00CAD$ 1,158.00 Business Monitor International, Oct 2008 , Pages: 92
  Australia Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Australia's pharmaceuticals and healthcare industry Despite dropping to joint second place...

• Genomics. Fundamentals and Applications

  EURO€ 208.00USD$ 270.00GBP£ 175.00AUD$ 264.00JPY¥ 26,658.00SEK 1 773,00CHF 254.00CAD$ 275.00 Informa Healthcare, Oct 2008 , Pages: 432
  This unique new text delivers a solid foundation for understanding the role of genomics in human health and in advances that promise to help improve the quality of human life. Unlike other works that...

• Global Markets for Neonatal/Perinatal Monitoring and Treatment Products: U.S., Europe, Rest of World

  EURO€ 4,608.00USD$ 5,995.00GBP£ 3,877.00AUD$ 5,864.00JPY¥ 591,904.00SEK 39 362,00CHF 5'650.00CAD$ 6,109.00 Life Science Intelligence, Oct 2008 , Pages: 150
  According to this report, the $1 2 billion 2008 global market for products used to monitor and treat neonatal and perinatal patients will grow at a CAGR of 5 2% reaching over $1 5 billion by 2013 Growth...

• 2009 U.S. Pharmaceutical Preparation Manufacturing Industry Report

  EURO€ 115.00USD$ 149.00GBP£ 96.00AUD$ 146.00JPY¥ 14,711.00SEK 978,00CHF 140.00CAD$ 152.00 Barnes Reports, Oct 2008 , Pages: 87
  The Pharmaceutical Preparation Mfg. Industry report, published annually, contains timely and accurate industry statistics, forecasts and demographics. The report features 2009 current and 2010 forecast...

• 2009 U.S. Pharmacies & Drug Stores Industry Report

  EURO€ 115.00USD$ 149.00GBP£ 96.00AUD$ 146.00JPY¥ 14,711.00SEK 978,00CHF 140.00CAD$ 152.00 Barnes Reports, Oct 2008 , Pages: 234
  The Pharmacies & Drug Stores Industry report, published annually, contains timely and accurate industry statistics, forecasts and demographics. The report features 2009 current and 2010 forecast estimates...

• Production, market and benchmarking of Carnitine in China

  EURO€ 9,224.00USD$ 12,000.00GBP£ 7,760.00AUD$ 11,737.00JPY¥ 1,184,796.00SEK 78 790,00CHF 11'310.00CAD$ 12,228.00 CCM International Limited, Oct 2008 , Pages: 110
  L-Carnitine, a natural and water soluble nutrient that can be produced by human body and also can be obtained from muscles, is an indispensable factor in the metabolism of fat and has many essential...

• Anatomy of the Heart by Multislice Computed Tomography

  EURO€ 86.00USD$ 112.00GBP£ 72.00AUD$ 110.00JPY¥ 11,069.00SEK 736,00CHF 106.00CAD$ 114.00 John Wiley and Sons Ltd, Oct 2008 , Pages: 136
  New MSCT machines produce a volume data set with the highest isotropic spatial resolution ever seen, offering superb 3D images of the entire heart and vessels. The texts currently available on cardiac...

• Emerging Infections 8

  EURO€ 112.00USD$ 145.00GBP£ 94.00AUD$ 142.00JPY¥ 14,344.00SEK 954,00CHF 137.00CAD$ 148.00 John Wiley and Sons Ltd, Oct 2008 , Pages: 472
  The twenty chapters in this volume provide concise and timely updates on the epidemiology, clinical features, and prevention and control strategies for a number of important emerging and reemerging...

• Saudi Arabia Pharmaceuticals and Healthcare Report Q4 2008

  EURO€ 874.00USD$ 1,137.00GBP£ 735.00AUD$ 1,112.00JPY¥ 112,215.00SEK 7 462,00CHF 1'071.00CAD$ 1,158.00 Business Monitor International, Oct 2008 , Pages: 71
  Saudi Arabia Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Saudi Arabia's pharmaceuticals and healthcare industry Saudi Arabia’s drug market is...

• Electronic Health Records: Interactions and Transactions Between Systems in an Ecosystem

  EURO€ 1,896.00USD$ 1,772.00GBP£ 1,077.00AUD$ 2,580.00JPY¥ 217,475.00SEK 15 293,00CHF 2'545.00CAD$ 2,369.00 Branham Group, Oct 2008 , Pages: 14
  Clinical reporting in primary care settings is predominantly paper driven Meanwhile, hospitals and acute care settings are working with a combined paper and electronic system Canada Health Infoway has...

• eHealth NOW: Alberta Update

  EURO€ 1,096.00USD$ 1,024.00GBP£ 623.00AUD$ 1,491.00JPY¥ 125,675.00SEK 8 838,00CHF 1'471.00CAD$ 1,369.00 Branham Group, Oct 2008 , Pages: 8
  Alberta has been the grounds for a great deal of change in 2008 The Alberta Health Services Board has replaced the nine Alberta regional health authority boards, the Alberta Mental Health Board, Alberta...

• China Vitamin Market Report, 2007-2008

  EURO€ 1,768.00USD$ 2,300.00GBP£ 1,487.00AUD$ 2,250.00JPY¥ 227,086.00SEK 15 101,00CHF 2'168.00CAD$ 2,344.00 Research In China, Oct 2008 , Pages: 89
  The period from 2003 to the end of 2006 had witnessed the rapid development of Chinese vitamin manufacturers, they had together played an important role in the international vitamin market via effective...

• China Vitamin Market Report, 2007-2008

  EURO€ 1,768.00USD$ 2,300.00GBP£ 1,487.00AUD$ 2,250.00JPY¥ 227,086.00SEK 15 101,00CHF 2'168.00CAD$ 2,344.00 Research In China, Oct 2008 , Pages: 89
  The period from 2003 to the end of 2006 had witnessed the rapid development of Chinese vitamin manufacturers, they had together played an important role in the international vitamin market via effective...

• Bulk Paclitaxel - Global Strategic Business Report

  EURO€ 3,053.00USD$ 3,450.00GBP£ 2,036.00AUD$ 4,771.00JPY¥ 413,720.00SEK 27 140,00CHF 4'544.00CAD$ 4,425.00 Global Industry Analysts, Inc, Oct 2008 , Pages: 232
  This report analyzes the worldwide markets for Bulk Paclitaxel in kilograms and US$ Million. The report provides separate comprehensive analytics for the US, and Rest of World. Annual forecasts are...

• Drug Discovery Technologies - Global Strategic Business Report

  EURO€ 3,496.00USD$ 3,950.00GBP£ 2,330.00AUD$ 5,462.00JPY¥ 473,679.00SEK 31 073,00CHF 5'202.00CAD$ 5,066.00 Global Industry Analysts, Inc, Oct 2008 , Pages: 675
  This report analyzes the worldwide markets for Drug Discovery Technologies in Millions of US$. The specific technology types analyzed are Bioanalytical Instruments, High Throughput Screening (HTS),...

• Launching a Medicine or a Product in French Pharmacies

  EURO€ 1,200.00USD$ 1,561.00GBP£ 1,010.00AUD$ 1,527.00JPY¥ 154,138.00SEK 10 250,00CHF 1'471.00CAD$ 1,591.00 Median Conseil, Oct 2008 , Pages: 98
  Many foreign companies would like to sell their products, medicinal or not, to French pharmacies but do not know how about doing so This study describes in detail: - What the different regulatory statuses...

• Emerging Medical Sensing Technologies

  EURO€ 4,996.00USD$ 6,500.00GBP£ 4,203.00AUD$ 6,357.00JPY¥ 641,764.00SEK 42 678,00CHF 6'126.00CAD$ 6,623.00 Frost & Sullivan, Sep 2008 , Pages: 126
  This research service provides an overview of the emerging sensing technologies in the field of healthcare This Frost & Sullivan research service titled Emerging Medical Sensing Technologies provides...

• Effective Drug Life Cycle Management: The Crucial Interaction Between Brand Life Span and Market Life Cycle

  EURO€ 865.00USD$ 1,125.00GBP£ 728.00AUD$ 1,100.00JPY¥ 111,075.00SEK 7 387,00CHF 1'060.00CAD$ 1,146.00 Decision Resources, Inc, Sep 2008 , Pages: 29
  Pharmaceutical companies recognize the importance of life cycle management but often focus on their own brands without taking note of the all-important market life cycle Companies need to understand...

• Pharma and the Feds: Key Government Activities and How They Affect the Biopharmaceutical Industry

  EURO€ 1,283.00USD$ 1,669.00GBP£ 1,079.00AUD$ 1,632.00JPY¥ 164,761.00SEK 10 957,00CHF 1'573.00CAD$ 1,700.00 Decision Resources, Inc, Sep 2008 , Pages: 44
  This is a critical time in U S history for examination of the delivery of healthcare services Some 47 million people in the United States lack healthcare coverage; the country spends $2 2 trillion annually...

• U.S. Stem Cell Market - Current Developments

  EURO€ 4,612.00USD$ 6,000.00GBP£ 3,880.00AUD$ 5,868.00JPY¥ 592,398.00SEK 39 395,00CHF 5'655.00CAD$ 6,114.00 Frost & Sullivan, Sep 2008
  This research service covers the U S stem cell market and current developments Included are disease overviews for main indications, estimated patient penetration for main indications, technology trends,...

• Strategic Analysis of Opportunities in the CRO Market - Phase 0

  EURO€ 4,996.00USD$ 6,500.00GBP£ 4,203.00AUD$ 6,357.00JPY¥ 641,764.00SEK 42 678,00CHF 6'126.00CAD$ 6,623.00 Frost & Sullivan, Sep 2008 , Pages: 48
  This strategic analysis study attempts to understand the opportunities for contract research organisations and pharmaceutical companies to take advantage of the inevitable choice of Phase zero or Microdosing...

• Women's Health Series: How Have New Oral Contraceptives Changed the Market?

  EURO€ 1,729.00USD$ 2,250.00GBP£ 1,455.00AUD$ 2,201.00JPY¥ 222,149.00SEK 14 773,00CHF 2'121.00CAD$ 2,293.00 Decision Resources, Inc, Sep 2008 , Pages: 21
  Introduction The oral contraceptive market is mature, with a high level of competition and a stable patient population Dozens of oral contraceptives are available worldwide; most are comparable in terms...

• Antidyslipidemics - Genericization and Negative Trial Data Drive Market Shrinkage

  EURO€ 11,684.00USD$ 15,200.00GBP£ 9,830.00AUD$ 14,867.00JPY¥ 1,500,741.00SEK 99 801,00CHF 14'327.00CAD$ 15,488.00 Datamonitor, Sep 2008
  The antidyslipidemic market is expected to fall to $20 billion in 2017. The decline will be driven by the deep genericization of the market, further exacerbated by the patent expiries of the top antidyslipidemic,...

• Practical Ultrasound in Anesthesia for Critical Care and Pain Management

  EURO€ 192.00USD$ 250.00GBP£ 162.00AUD$ 245.00JPY¥ 24,683.00SEK 1 641,00CHF 236.00CAD$ 255.00 Informa Healthcare, Sep 2008 , Pages: 288
  Practical Ultrasound in Anesthesia for Critical Care and Pain Management is a stand-alone comprehensive reference that covers important aspects of ultrasound for the practicing anesthesiologist. Beginning...